$599

Zealand and Roche Partner for Ph3 stable glucagon development in CHI

Zealand has announced a collaboration with Roche for the Ph3 development of Zealand’s dasiglucagon for the treatment of congenital hyperinsulinism. Below, FENIX further analyzes this scenario.

This content is for Read Less members only.
Register
Already a member? Log in here